Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1519 | 2528 | 31.4 | 65% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1835 | 5652 | SMALL CELL LUNG CANCER//BOMBESIN//GASTRIN RELEASING PEPTIDE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SMALL CELL LUNG CANCER | Author keyword | 309 | 36% | 27% | 695 |
2 | AMRUBICIN | Author keyword | 102 | 72% | 3% | 79 |
3 | PROPHYLACTIC CRANIAL IRRADIATION | Author keyword | 40 | 47% | 2% | 63 |
4 | EXTENSIVE STAGE | Author keyword | 39 | 80% | 1% | 24 |
5 | LIMITED DISEASE | Author keyword | 36 | 71% | 1% | 29 |
6 | LIMITED STAGE | Author keyword | 29 | 63% | 1% | 30 |
7 | LIMITED STAGE SMALL CELL LUNG CANCER | Author keyword | 25 | 77% | 1% | 17 |
8 | EXTENSIVE DISEASE | Author keyword | 25 | 75% | 1% | 18 |
9 | SENSITIVE RELAPSE | Author keyword | 21 | 90% | 0% | 9 |
10 | AMRUBICINOL | Author keyword | 21 | 85% | 0% | 11 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SMALL CELL LUNG CANCER | 309 | 36% | 27% | 695 | Search SMALL+CELL+LUNG+CANCER | Search SMALL+CELL+LUNG+CANCER |
2 | AMRUBICIN | 102 | 72% | 3% | 79 | Search AMRUBICIN | Search AMRUBICIN |
3 | PROPHYLACTIC CRANIAL IRRADIATION | 40 | 47% | 2% | 63 | Search PROPHYLACTIC+CRANIAL+IRRADIATION | Search PROPHYLACTIC+CRANIAL+IRRADIATION |
4 | EXTENSIVE STAGE | 39 | 80% | 1% | 24 | Search EXTENSIVE+STAGE | Search EXTENSIVE+STAGE |
5 | LIMITED DISEASE | 36 | 71% | 1% | 29 | Search LIMITED+DISEASE | Search LIMITED+DISEASE |
6 | LIMITED STAGE | 29 | 63% | 1% | 30 | Search LIMITED+STAGE | Search LIMITED+STAGE |
7 | LIMITED STAGE SMALL CELL LUNG CANCER | 25 | 77% | 1% | 17 | Search LIMITED+STAGE+SMALL+CELL+LUNG+CANCER | Search LIMITED+STAGE+SMALL+CELL+LUNG+CANCER |
8 | EXTENSIVE DISEASE | 25 | 75% | 1% | 18 | Search EXTENSIVE+DISEASE | Search EXTENSIVE+DISEASE |
9 | SENSITIVE RELAPSE | 21 | 90% | 0% | 9 | Search SENSITIVE+RELAPSE | Search SENSITIVE+RELAPSE |
10 | AMRUBICINOL | 21 | 85% | 0% | 11 | Search AMRUBICINOL | Search AMRUBICINOL |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | 9 AMINOANTHRACYCLINE | 135 | 97% | 1% | 37 |
2 | CROSS RESISTANT CHEMOTHERAPY | 122 | 79% | 3% | 77 |
3 | THORACIC RADIOTHERAPY | 99 | 38% | 8% | 206 |
4 | CISPLATIN PLUS ETOPOSIDE | 86 | 84% | 2% | 47 |
5 | PROPHYLACTIC CRANIAL IRRADIATION | 81 | 35% | 7% | 189 |
6 | ANTHRACYCLINE DERIVATIVE SM 5887 | 61 | 95% | 1% | 20 |
7 | ETOPOSIDE CISPLATIN | 58 | 68% | 2% | 52 |
8 | RESEARCH CAMPAIGN TRIAL | 48 | 91% | 1% | 20 |
9 | DAILY THORACIC RADIOTHERAPY | 46 | 82% | 1% | 27 |
10 | SM 5887 | 45 | 94% | 1% | 16 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Management of Small Cell Lung Cancer Recent Developments for Optimal Care | 2012 | 25 | 88 | 77% |
Treatment of patients with small-cell lung cancer: From meta-analyses to clinical practice | 2013 | 13 | 34 | 91% |
Small cell lung cancer | 2008 | 97 | 104 | 54% |
Small-cell lung cancer | 2005 | 218 | 136 | 49% |
Small Cell Lung Cancer: Therapies and Targets | 2014 | 5 | 85 | 72% |
Small cell lung cancer | 2003 | 68 | 71 | 92% |
Chemotherapy advances in small-cell lung cancer | 2013 | 9 | 84 | 81% |
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis | 2000 | 93 | 45 | 87% |
Treatment options for small cell lung cancer - do we have more choice? | 2010 | 28 | 73 | 84% |
Chemotherapy for small cell lung cancer | 2003 | 63 | 58 | 88% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SOTIRIA HOSP ATHENS | 4 | 75% | 0.1% | 3 |
2 | LUNG THORAC TUMORS | 2 | 67% | 0.1% | 2 |
3 | MED ONCOL B171 | 2 | 67% | 0.1% | 2 |
4 | THORA SURG | 2 | 67% | 0.1% | 2 |
5 | INTERNAL MED THORAC ONCOL | 2 | 16% | 0.4% | 10 |
6 | PULM DIS 1 | 1 | 31% | 0.2% | 4 |
7 | MIDDLESEX HOSP MED ONCOL | 1 | 50% | 0.1% | 2 |
8 | SECT BIOMED STAT INFORMAT | 1 | 100% | 0.1% | 2 |
9 | THORAC MALIGNANCY | 1 | 13% | 0.4% | 9 |
10 | PULM DIS 2 | 1 | 30% | 0.1% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000106224 | ETOPOSIDE PHOSPHATE//ETOPOSIDE//ORAL ETOPOSIDE |
2 | 0.0000097272 | SMALL CELL LUNG CANCER CELL LINE//SMALL CELL LUNG CANCER CELL LINES//DRUG SCREENING ASSAY |
3 | 0.0000075701 | VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER |
4 | 0.0000068021 | LARGE CELL NEUROENDOCRINE CARCINOMA//TYPICAL CARCINOID//ATYPICAL CARCINOID |
5 | 0.0000064139 | STAGE III//LOCALLY ADVANCED NON SMALL CELL LUNG CANCER//ACUTE ESOPHAGITIS |
6 | 0.0000057655 | EXOCERVIX//MUCOSAL LEUKOCYTES//IMMUNOBIOL CELL DIFFERENTIAT UNIT |
7 | 0.0000056367 | INMUNOFERON//GLYCOPHOSPHOPEPTICAL//AM3 |
8 | 0.0000050450 | EXTRAPULMONARY SMALL CELL CARCINOMA//SMALL CELL CARCINOMA//SMALL CELL CARCINOMA OF THE ESOPHAGUS |
9 | 0.0000045930 | CYFRA 21 1//CYTOKERATIN 19 FRAGMENTS//PROGRP |
10 | 0.0000040910 | BRAIN METASTASES//WHOLE BRAIN RADIOTHERAPY//WHOLE BRAIN RADIATION THERAPY |